Study finds that high levels of the fetal hormone GDF15 in mothers are linked to an increased risk of nausea, vomiting, and hyperemesis gravidarum in pregnancy, offering new insights into the condition’s etiology.
AbbVie inks deal with Parvus; Sofinnova invests in Cure51
Plus, news about Aquestive Therapeutics and Cybin: AbbVie enlists Parvus Therapeutics for IBD pact: AbbVie will have the option to develop and commercialize Parvus’ therapies